Yasmin L. Hurd
Broadly activating innate immunity, which has been achieved via unrelated vaccines or Type-I INF-like factors, may effectively treat or prevent COVID-19 and future coronavirus diseases.
Leonard Angka, Marisa Market, Michele Ardolino, Rebecca C. Auer
Lucy Y. Ghoda, Steven T. Rosen, Larry W. Kwak
David T. Ting, Julius J.S. Knowles
Norman E. Sharpless
In COVID-19, complement activation may contribute to hemostatic activation leading to pathological features such as microvascular injury and coagulopathy.
Wen-Chao Song, Garret A. FitzGerald
Mark Donowitz, Jerrold R. Turner, Alan S. Verkman, Nicholas Constantine Zachos
Laura E. Crotty Alexander, Amy L. Bellinghausen, Michelle N. Eakin
This Viewpoint calls on investigators that are developing and testing therapeutic and prophylactic approaches for COVID-19 to design studies that are inclusive of male-female differences.
Evelyne Bischof, Jeannette Wolfe, Sabra L. Klein
Medications that target catecholamine-associated inflammation may prevent cytokine storm syndrome associated with COVID-19 and other diseases.
Maximilian F. Konig, Michael A. Powell, Verena Staedtke, Ren-Yuan Bai, David L. Thomas, Nicole M. Fischer, Sakibul Huq, Adham M. Khalafallah, Allison Koenecke, Ruoxuan Xiong, Brett Mensh, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Joshua T. Vogelstein, Susan Athey, Shibin Zhou, Chetan Bettegowda
No posts were found with this tag.